Preview

Артериальная гипертензия

Расширенный поиск

Роль сахароснижающих препаратов в контроле артериального давления у пациентов с сахарным диабетом 2 типа

https://doi.org/10.18705/1607-419X-2015-21-4-334-348

Полный текст:

Аннотация

Высокий вклад в развитие сосудистых осложнений сахарного диабета 2‑го типа (СД2) не только гипергликемии, но и таких компонентов синдрома инсулинорезистентности, как ожирение, дислипидемия и артериальная гипертензия (АГ), диктует необходимость учитывать влияние на них различных факторов. Начало XXI века характеризуется появлением целого ряда новых фармакологических агентов для лечения СД2, а также изменением концепции подхода к лечению с глюкоцентрической на многофакторную. Создание новых групп противодиабетических препаратов (ПП) с множественными негликемическими эффектами существенно усложнило выбор терапии для каждого конкретного больного и, несомненно, требует расширения знаний специалистов в этой области. Настоящий обзор посвящен одному из негликемических эффектов — влиянию различных групп ПП на уровень артериального давления у пациентов с СД2. Мы надеемся, что представленная работа позволит врачам лучше ориентироваться в выборе ПП при СД2 и сопутствующей АГ и принимать оптимальные решения в каждом индивидуальном случае.

Об авторе

А. Ю. Бабенко
Федеральное государственное бюджетное учреждение «Северо-Западный федеральный медицинский исследовательский центр имени В.А. Алмазова» Министерства здравоохранения Российской Федерации; Государственное бюджетное образовательное учреждение высшего профессионального образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова» Министерства здравоохранения Российской Федерации
Россия

доктор медицинских наук, заведующая научно-исследовательской лабораторией диабетологии Института эндокринологии, пр. Пархоменко, д. 15, Санкт-Петербург, 194156;

доцент кафедры терапии факультетской с курсом эндокринологии имени Г.Ф. Ланга, Санкт-Петербург



Список литературы

1. Nolan C, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378(9786):169–181. doi: 10.1016/S0140–6736 (11)60614–4

2. Grundy S, Howard B, Smith S, Jr Eckel R, Redberg R, Bonow R. Prevention Conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002;105(18):2231–2239.

3. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J. 1998;317 (7175):703–713. doi: 10.1136/bmj.321.7258.405

4. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med. 2000;342(13):905–912. doi: 10.1056/NEJM200008243430813

5. Solomaa VV, Strandberg TE, Vanhanem H, Naukkarinen V, Sarna S, Mietlinen TA. Glucose tolerance and blood pressure: long term follow up in middle aged men. BMJ. 1991;302(6775): 493–496.

6. D’Agostino RB, Vasan RS, Pencina MJ. General cardiovascular risk profile for use in primary care. The Framingham Heart Study. Circulation. 2008;117(6):743–753.

7. Triggle CR, Ding Н. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014;5 (6):245–268. doi: 10.1177/2040622314546125

8. Бабенко А.Ю., Красильникова Е.И., Лихоносов Н.П., Лихоносова А.П., Гринёва Е.Н. Влияние различных групп сахароснижающих препаратов на вариабельность гликемии у больных сахарным диабетом 2 типа. Сахарный диабет. 2014;4:72–80. doi: 10.14341/DM20144. [Babenko AY, Krasilnikova EI, Likhonosov NP, Likhonosova AP, Grineva EN. The impact of different antidiabetic drugs on glycemic variability in type 2 diabetes mellitus. Sakharniy Diabet = Diabetes Mellitus. 2014;4:72–80. doi: 10.14341/DM20144. In Russian].

9. Ajjan R, Grant P. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res. 2006;3(3):147–158.

10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.

11. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a metaanalysis of randomized clinical trials. Diabetes Obes Metab. 2011;13 (3):221–228. doi: 10.1111/j.1463–1326.2010.01349

12. Viollet В, Guigas В, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview/Clin Sci (Lond). 2012;122(6):253–270. doi: 10.1042/CS20110386.

13. Кравчук Е.Н., Галагудза М.М. Применение метформина при сочетании ишемической болезни сердца и сахарного диабета 2 типа: механизмы действия и клиническая эффективность. Сахарный диабет. 2013;1:5–14. [Kravchuk EN, Galagoudza MM, Metformin in co-existent coronary artery disease and type 2 diabetes mellitus: mechanisms and clinical efficiency. Sakharniy Diabet = Diabetes Mellitus. 2013;1:5–14. In Russian].

14. De Jager J, Kooy A, Lehert P, Bets D, Wulffelé M, Teerlink T et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. JIntern Med. 2005;257(1):100–109.

15. Detaille D, Guigas B, Chauvin C, Batandier C, Fontaine E, Wiernsperger N et al. Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. Diabetes. 2005;54(7):2179–2187.

16. Wulffele MG, Kooy A, De Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med. 2004;256(1):1–14. DOI: 10.1111/j.1365–2796.2004.01328

17. University Group Diabetes Program: Study of the effect of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19 (Suppl 2):789–830.

18. Stephan D, Winkler M, Kühner P, Russ U, Quast U. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K (ATP) channels. Diabetologia. 2006;49(9):2039–2048. DOI: 10.1007/s00125–006–0307–3

19. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, de Peppo A et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994;90(2):700–705.

20. Brayden JE, Nelson MT. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science. 1992;256(5056):532–535.

21. Spanswick D, Smith MA, Groppi VE, Logan SD, Ashford MLJ. Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels. Nature. 1997;390(6659): 521–525.

22. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25(11):2058–2064. doi: 10.2337/diacare.25.11.2058

23. Belcher G, Lambert C, Goh KL, Edwards G, Valbuena M. Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazide. Int J Clin Pract. 2004;58(9):833–837. doi: 10.2337/dc09‑S335

24. Roumie CL, Liu X, Choma NN, Greevy RA, Hung AM, Grijalva CG et al. Initiation of sulfonylureas versus metformin is associated with higher blood pressure at one year. Pharmacoepidemiol Drug Saf. 2012;21(5):515–523. doi: 10.1002/pds.3249.

25. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A et al. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study) The RECORD Study Group. Cardiovasc Diabetol. 2008;7:10–17. doi:10.1186/1475–2840–7-10

26. Mahaffey K, Hafley G, Dickerson S, Burns S, TourtUhlig S, White J et al. Results of a reevaluation of cardiovascular outcomesin the RECORD trial. Am Heart J. 2013;166 (2):240–249. DOI: http://dx.doi.org/10.1016/j.ahj.2013.05.004

27. Dorkhan M, Dencker M, Stagmo M, Groop L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8:15–20. doi: 10.1186/1475–2840–8–15.

28. Defronzo R, Mehta R, Schnure J. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract. 2013;41(2):132–147.

29. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20 (5):649–688.

30. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25 (2):376–380.

31. Hsueh WA, Bruemmer D. Peroxisome proliferatoractivated receptor gamma: implications for cardiovascular disease. Hypertension. 2004;43(2):297–305.

32. Fukunaga Y, Itoh H, Doi K, Tanaka T, Yamashita J, Chun TH et al. Thiazolidinediones, peroxisome proliferatoractivated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis. 2001;158 (1):113–119.

33. Qayyum R, Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hyper. 2006;8 (1):19–28. doi: 10.1111/j.1524–6175.2005.04784.x

34. Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Matas D, Zimlichman R: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens. 2003;16(8):617–622. doi: 10.1016/S0895–7061 (03)00911–7

35. Song J, Walsh MF, Igwe R, Ram JL, Barazi M, Dominguez LJ. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production. Diabetes. 1997;46(4):659–664.

36. Chiasson J‑L, Josse RG, Gomis R, Hanefeld M, KarasikA, Laakso M. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance: The STOP-NIDDM Trial. J Am Med Assoc. 2003;290 (4):486–494. doi:10.1001/jama.290.4.486

37. Hanefeld MG. Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction. Eur Heart J. 2004;25(13):1179–1180. doi: http://dx.doi.org/10.1016/j.ehj.2004.01.0271179–1180

38. Schernthaner G, Mogensen CE, Schernthaner GH. The effects of GLP‑1 analogues, DPP‑4 inhibitors and SGLT2 inhibitors on the renal system. Diabetes Vasc Dis Res. 2014;11(5):306–323.

39. Дедов И.И., Шестакова М.В. Инкретины: новая веха в лечении сахарного диабета 2 типа. Москва, 2010. C. 55–62. [Dedov II, Shestakova MV. Incretines: new landmark in the treatment of type 2 diabetes mellitus. Moscow, 2010. P. 55–62. In Russian].

40. GuptaV. Pleiotropic effects ofincretins. Indian J Endocrinol Metab. 2012; 16 (Suppl 1): S47–S56. doi: 10.4103/2230–8210.94259

41. Panchapakesan U, Mather A, Pollock C. Role of GLP‑1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Scien. 2013;124(1):17–26. doi: 10.1042/CS20120167

42. Mosenzon O, Raz I. Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials. Eur Heart J. 2012;14 (Suppl B): B22–B29. doi:10.1093/eurheartj/sus003

43. Russell-Jones D. The safety and tolerability of GLP‑1 receptor agonistsin the treatment of type 2 diabetes. Int J Clin Pract. 2010;64 (10):1402–1414. doi: 10.1111/j.1742–1241.2010.02465

44. Green B, Hand K, Dougan J, McDonnell B, Cassidy R, Grieve D. GLP-1 and related peptides cause concentrationdependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys. 2008;478(2):136–142. doi: 10.1016/j.abb.2008.08.001.

45. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diab Obes Metab. 2013;15(8):737–749. doi: 10.1111/dom.12085

46. Koibuchi N, Hasegawa Y, Katayama T, Toyama K, Uekawa K, Sueta D et al. DPP‑4 inhibitor linagliptin ameliorates cardiovascularinjury in salt-sensitive hypertensive ratsindependently of blood glucose and blood Pressure. Cardiovasc Diabetol. 2014;13:157.

47. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension. 2008;51(6):1637–1642. doi: 10.1161/HYPERTENSIONAHA.108.112532

48. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I et al. Acute DPP-4 inhibition modulates vascular tone through GLP‑1 independent pathways. Vascul Pharmacol. 2011;55 (1–3):2–9. doi: 10.1016/j.vph.2011.03.001

49. Rizzo M, Nikolic D, Banach M, Patti AM, Montalto G, Rizvi AA. Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation. Curr Pharmac Des. 2014;20 (31):4953–4960. doi:1381–6128/14 $58.00+.00

50. Takasawa W, Ohnuma K, Hatano R, Endo Y, Dang N, Morimoto C. Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochem Biophys Res Commun. 2010;401(1):7–12. doi: 10.1016/j.bbrc.2010.08.112

51. Mason RP, Jacob RF, Kubant R, Ciszewski A, Corbalan JJ, Malinski T. Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats. J Cardiovasc Pharmacol. 2012;60(5):467–473. doi: 10.1097/FJC.0b013e31826be204

52. Liu L, Liu J, Wong WT, Tian XY, Lau CW, Wang YX et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1‑dependent mechanism. Hypertension. 2012;60 (3):833–841. doi: 10.1161/HYPERTENSIONAHA.112.195115

53. Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA et al. Effect of sitagliptin, a dipeptidyl peptidase‑4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592–598. DOI: 10.1177/0091270008316885

54. Cakirca M, Karatoprak C, Zorlu M, Kiskac M, Kanat M, Cikrikcioglu MA et al. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients. Drug Des Devel Ther. 2014;8:239–243.

55. Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, Eynatten M. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care. 2013;36(11):3460–3468. doi: 1479 164115579002

56. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728–733.doi: 10.1161/ HYPERTENSIONAHA. 110.156554

57. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension. 2015;65:238–249. doi:10.1161/.114.04631

58. Sun AL, Deng JT, Guan GJ, Chen SH, Liu YT, Cheng J. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res. 2012;9 (4):301–308. doi: 10.1177/1479164111434318

59. Bakris GL. High blood pressure. In: The Merck manual home health handbook. 19th ed. Available at http:.www.merckmanuals.com/home/heart_and_blood_vessel_ disorders/high_blood_pressure/high_blood_pressure.html. Accessed September 3, 2013.

60. Oliva RV, Bakris GL. Blood pressure effects of sodiumglucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–339. doi.org/10.1016/j.jash.2014.02.003

61. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–42. doi: 10.1111/j.1464–5491

62. Cherney DZI, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28. doi:10.1186/1475–2840–13–28

63. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Int Med. 2013;159(4):262–274.

64. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose cotransporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262–275. http://dx.doi.org/10.1016/j.jash.2014.01.007

65. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS et al. American association of clinical endocrinologists and American college of endocriniligy — clinical practice guidelines for developing a diabetes mellitus comprehensive care plan — 2015. AACE/ACE Diabetes Guidelines. Endocr Pract. 2015;21(Suppl 1):1–87. doi:10.4158/EP15672.GL.

66. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Update to a position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2015;38(1):140–149. [PubMed: 22517736]

67. Alter ML, Ott IM, von Websky K, Tsuprykov O, Sharkovska Y, Krause-Relle K et al. DPP‑4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res. 2012;36(1):119–130. doi: 10.1159/000341487


Для цитирования:


Бабенко А.Ю. Роль сахароснижающих препаратов в контроле артериального давления у пациентов с сахарным диабетом 2 типа. Артериальная гипертензия. 2015;21(4):334-348. https://doi.org/10.18705/1607-419X-2015-21-4-334-348

For citation:


Babenko A.Y. The role of glucose-lowering drugs in blood pressure control in patients with type 2 diabetes mellitus. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(4):334-348. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-4-334-348

Просмотров: 431


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)